Multivalent conjugate vaccines with bivalent or multivalent conjugate polysaccharides that provide improved immunogenicity and avidity
The disclosure describes compositions containing conjugates using novel linkers, bivalent polysaccharide conjugates, and methods of bivalent polysaccharide conjugation in the development of multivalent conjugate vaccines. Conjugation of capsular polysaccharides to carrier proteins is carried out using homo-bifunctional and/or hetero-bifunctional linkers of specific lengths. Incorporation of the linkers and their use in bifunctional linkers induces higher titers of functional antibodies with high avidity, eliciting higher immunologic memory, and reduced carrier protein effect. This provides immunochemically cross-reactive capsular polysaccharides wherein one or more cross-reactive capsular polysaccharides are conjugated sequentially or concurrently to carrier protein using bifunctional linkers bearing the same or different functional groups. Such a linker and the size of the capsular polysaccharides provides an effective multivalent conjugate vaccine with high antibody titers and a reduced carrier effect and results in reduction in the content of the capsular polysaccharide and protein per dose of vaccine which reduces reactogenicity.
1. An immunogenic composition comprising:
first and second group conjugates, wherein:
first group conjugates comprise a first collection of monovalent conjugates, wherein each monovalent conjugate comprises a first carrier protein and a capsular polysaccharide of Streptococcus pneumoniae and the first collection includes capsular polysaccharides of Streptococcus pneumoniae serotypes 1, 2, 3, 4, 5, 7F, 8, 10A, 11A, 12F, 14, 17F, 18C, 20, 22F, 23F, 24F, 33F and 35B; and
second group conjugates comprise a second collection of bivalent and/or multivalent conjugates, wherein each bivalent or multivalent conjugate comprises a second carrier protein and at least two capsular polysaccharides of Streptococcus pneumoniae , selected from one or more of the groups consisting Streptococcus pneumoniae serotypes 6A, 6B, 6C, and and/or 6D, Streptococcus pneumoniae serotypes 9V, 9N, 9A and 9B, Streptococcus pneumoniae serotypes 15B, 15A, and 15C, and Streptococcus pneumoniae serotypes 19A and 19F, wherein one or more of the capsular polysaccharides are coupled via a bifunctional linker, wherein the multivalent conjugate contains a quantity of carrier protein that is less than a quantity of capsular polysaccharide.
2. The immunogenic composition of claim 1 , wherein the second group conjugates are bivalent conjugates.
3. The immunogenic composition of claim 2 , wherein the bivalent conjugates comprises two immunologically cross-reactive serotypes represented by the formula PS1-Carrier Protein-PS2, wherein PS1 and PS2 represent different polysaccharides and carrier protein refers to the second carrier protein.
4. The immunogenic composition of claim 2 , wherein the bivalent conjugates are conjugated to the same carrier protein sequentially or concurrently.
5. The immunogenic composition of claim 1 , wherein the second group conjugates comprise bivalent conjugates and the capsular polysaccharides of the bivalent conjugates have a molecular weight of from 10 kDa to 50 kDa.
6. The immunogenic composition of claim 1 , wherein the bifunctional linker further comprises a spacer arm of from 9-40 Å.
7. The immunogenic composition of claim 1 , wherein the first carrier protein and/or the second carrier protein comprises tetanus toxoid, diphtheria toxoid, CRM197, tetanus toxoid fragments (TTHc), N. meningitidis protein PorB, RSV virus proteins, Bordetella pertussis proteins, Pertussis toxoid (PT), adenylate cyclase toxin (ACT), Human Papilloma viral protein antigens, a Human Papilloma viral 69 KDa protein, Human Papilloma virus VLP forms, Hepatitis B virus core antigen, Hepatitis B virus VLP forms, derivatives of HBsAg, and/or combinations thereof.
8. The immunogenic composition of claim 1 , wherein a single dose comprises less than 4 micrograms.
9. The immunogenic composition of claim 1 , wherein the quantity of the first and second carrier proteins is from 0.5% to 0.8%, by weight, of the conjugates.
10. The immunogenic composition of claim 1 , wherein the second group conjugates comprise bivalent conjugates and the capsular polysaccharides of the bivalent conjugates have a molecular weight of from 30 KDa-100 KDa.
11. The immunogenic composition of claim 1 , wherein one or more of the monovalent conjugates comprise a linker.
12. The immunogenic composition of claim 1 , further comprising at least one adjuvant selected from the group consisting of aluminum salt, calcium phosphate, a liposome of monophosphoryl lipid A (MPLA), saponin QS-21, and a potent TLR7/8 agonist.
13. The immunogenic composition of claim 12 , wherein the aluminum salt is selected from the group consisting of aluminum phosphate, aluminum sulfate and aluminum hydroxide.
14. The immunogenic composition of claim 1 , wherein the second collection includes Streptococcus pneumoniae serotypes 6A, 6B, 6C, and 6D, Streptococcus pneumoniae serotypes 9V, 9N, 9A and 9B, Streptococcus pneumoniae serotypes 15B, 15A, and 15C, and Streptococcus pneumoniae serotypes 19A and 19F.
15. The immunogenic composition of claim 14 , further comprising capsular polysaccharides of one or more serotypes of Haemophilus influenza type a and/or b; Group B Streptococcus, Moraxella catarrhalis lipo-oligosaccharides (LOS), non-typable Haemophilus influenzae (NTHi) and/or Neisseria meningitis.
16. The immunogenic composition of claim 1 , wherein the second group conjugates comprise bivalent conjugates and the capsular polysaccharides of the bivalent conjugates have a molecular weight of from 100 KDa-300 KDa.
17. The immunogenic composition of claim 1 , wherein administration of a single dose generates a lower immune response to the carrier protein in comparison to administration of a similar conjugate containing only monovalent conjugates of the same polysaccharides.